GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
Go back to GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide| (NASDAQ: GDRX) | Delayed: 2.57 -0.09 (3.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.66 | 52 Week High | $ | |||
| Open | $2.64 | 52 Week Low | $ | |||
| Day High | $2.71 | P/E | N/A | |||
| Day Low | $2.57 | EPS | $ | |||
| Volume | 1,869,184 | |||||
